GlaxoSmithKline (GSK, Financial) announced positive outcomes from late-stage trials for its experimental drug, Depemokimab, aimed at treating a common form of rhinitis. The trials indicated that Depemokimab effectively reduces nasal congestion and the size of polyps in patients suffering from chronic sinusitis with nasal polyps, a condition affecting up to 4% of the population. Approximately 40% of these patients reportedly struggle to control their symptoms.
Following this announcement, GSK's stock rose about 1% in premarket trading. The stock has seen a 2.3% increase since the beginning of the year. Depemokimab is considered crucial for GSK's growth strategy over the upcoming years, with a potential launch aimed for 2026-2027 across various diseases. The company projects that the annual sales of Depemokimab could reach up to £3 billion ($3.9 billion). This long-acting injectable is administered once every six months and has also shown promise in preventing severe asthma attacks.
Complete trial results for Depemokimab's use in treating chronic sinusitis with nasal polyps will be disclosed at an upcoming scientific conference.
